Edition:
United Kingdom

FibroGen Inc (FGEN.OQ)

FGEN.OQ on NASDAQ Stock Exchange Global Select Market

59.30USD
20 Aug 2018
Change (% chg)

-- (--)
Prev Close
$59.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
150,513
52-wk High
$68.15
52-wk Low
$40.35

Latest Key Developments (Source: Significant Developments)

Astellas, Fibrogen Announce Topline Results From Japan Phase 3 Study Of Roxadustat
Thursday, 31 May 2018 

May 31 (Reuters) - Astellas Pharma Inc <4503.T>::ASTELLAS & FIBROGEN ANNOUNCE TOPLINE RESULTS FROM DOUBLE-BLIND JAPAN PHASE 3 STUDY FOR ROXADUSTAT IN HEMODIALYSIS CHRONIC KIDNEY DISEASE PATIENTS WITH ANEMIA.ASTELLAS PHARMA INC - FOURTH JAPAN PHASE 3 STUDY FOR ROXADUSTAT MET ITS PRIMARY ENDPOINT.ASTELLAS PHARMA INC - ROXADUSTAT WAS WELL TOLERATED IN STUDY.ASTELLAS PHARMA INC - SAFETY PROFILE OF ROXADUSTAT WAS CONSISTENT WITH THAT OBSERVED IN PREVIOUS STUDIES BOTH IN DIALYSIS AND NON-DIALYSIS PATIENTS.  Full Article

Fibrogen Inc reports Q3 loss per share $0.50
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Fibrogen Inc ::Fibrogen reports third quarter 2017 financial results.Q3 loss per share $0.50.Q3 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S.nda filing for roxadustat for anemia in​ ckd with u.s. Food and drug administration targeted for 2018.qtrly ‍total revenue $27.3 million versus $30.1 million.  Full Article

Fibrogen announces acceptance by china FDA of roxadustat NDA for treatment of anemia associated with dialysis and non-dialysis kidney disease
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Fibrogen Inc :Fibrogen announces acceptance by china FDA of roxadustat new drug application (NDA) for treatment of anemia associated with dialysis and non-dialysis chronic kidney disease (CKD).Fibrogen - ‍under terms of Fibrogen's agreement with Astrazeneca, NDA submission triggers a $15 million milestone payment, payable to co by Astrazeneca​.  Full Article

BRIEF-FibroGen Reports Q1 Loss Per Share $0.50

* Q1 EARNINGS PER SHARE VIEW $-0.51 -- THOMSON REUTERS I/B/E/S